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in Dendritic Cells Independently
of Invariant Chain Degradation
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are loaded into the MHC II peptide binding groove with
the assistance of the chaperones H-2DM and H-2DO
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(Kropshofer et al., 1999). Antigen presentation by B cellsMelbourne
and DC from Cat S/ mice is compromised due toVictoria 3050
impairment of Iip10 degradation, illustrating the key role2 Department of Microbiology and Immunology
of Cat S (Nakagawa et al., 1999; Shi et al., 1999). How-Melbourne University
ever, the importance of Cat S varies among mouseParkville
strains: some MHC II allelic products (for instance,Victoria 3052
I-Ak, q, s, and u) generate -peptide complexes even in theAustralia
absence of Cat S, probably because Iip10 can be ex-
pelled directly from their peptide binding site (Figure 7)
(Nakagawa et al., 1999; Villadangos et al., 1997).Summary
DC are professional APC that possess specific mech-
anisms to initiate immune responses (Banchereau etWe have investigated the mechanisms that control
al., 2000). In peripheral tissues, DC are specialized atMHC class II (MHC II) expression in immature and
capturing antigens (Sallusto et al., 1995). The MHC II ofactivated dendritic cells (DC) grown from spleen and
these “immature” DC are expressed at low levels atbone marrow precursors. Degradation of the MHC II
the plasma membrane but are abundant in endocyticchaperone invariant chain (Ii), acquisition of peptide
compartments. However, when DC are activated by in-cargo by MHC II, and delivery of MHC II-peptide com-
flammatory stimuli, they stop capturing antigens (Garrettplexes to the cell surface proceeded similarly in both
et al., 2000) and express at their plasma membraneimmature and activated DC. However, immature DC
high levels of MHC II loaded with peptides derived fromreendocytosed and then degraded the MHC II-peptide
antigens captured at the site of inflammation (Cella etcomplexes much faster than the activated DC. MHC
al., 1997; Inaba et al., 2000; Pierre et al., 1997; Turley etII expression in DC is therefore not controlled by the
al., 2000). Simultaneously, the mature DC migrate toactivity of the protease(s) that degrade Ii, but by the
lymphoid organs and upregulate the costimulatory mol-rate of endocytosis of peptide-loaded MHC II. Late
ecules necessary to activate naive T cells.after activation, DC downregulated MHC II synthesis
What are the mechanisms that control MHC II expres-both in vitro and in vivo.
sion in DC? A current model suggests that modulation
of Cat S activity plays a pivotal role (Pierre and Mellman,Introduction
1998). The presence of the natural protease inhibitor
Cystatin C (CyC) in the MIIC compartments of immatureAntigen presentation is a key event in the initiation and
DC would inhibit Cat S, preventing the degradation ofdevelopment of T cell-mediated immune responses.
Iip10. The resulting -Iip10 complexes would then beMHC class II molecules (MHC II) present peptide anti-
transported to lysosomes, due to targeting signals en-gens derived mostly from endogenous and exogenous
coded in the cytoplasmic region of Ii (and Iip10), andproteins that access the endocytic route, where they
degraded. In mature DC, CyC would be downregulated
are degraded (Lich et al., 2000; Santambrogio et al.,
and removed from MIIC compartments, enabling Cat
1999; Watts, 1997). The MHC II  dimers assemble
S to fully degrade Iip10, thus allowing MHC II to bind
in the endoplasmic reticulum (ER) with the chaperone antigenic peptides and shuttle to the cell surface.
invariant chain (Ii), whose CLIP region occupies the pep- We have assessed by immunofluorescence confocal
tide binding site of the  dimer (Figure 7). Ii also con- microscopy (ICM) and biochemical analysis the distribu-
tains in its cytoplasmic tail a motif that directs the deliv- tion, processing, and trafficking of MHC II in immature
ery and retention of the Ii complexes into the and activated DC grown in vitro from bone marrow- or
endocytic route (Bakke and Dobberstein, 1990). Once spleen-derived precursors. Both immature and acti-
there, Ii must be removed to allow the formation of - vated DC degraded Ii and generated peptide-loaded
peptide complexes, which are then delivered to the cell MHC II complexes with comparable kinetics, but imma-
surface for recognition by the T cells. ture DC quickly degraded the peptide-loaded MHC II
Ii is degraded in stages in the so-called CIIV and MIIC complexes after their transient expression at the plasma
compartments of the endocytic route (reviewed in Villa- membrane. Moreover, DC controlled the trafficking of
dangos and Ploegh, 2000). The last stage is the cleavage both the Cat S-dependent I-Ab and the Cat S-indepen-
of Iip10, an intermediate that extends from the cyto- dent I-As allotypes, a finding that argues against Cat S
plasmic N-terminal end of Ii until the C-terminal region being a regulatory element of MHC II trafficking in DC.
of CLIP (Figure 7). Then, Iip10 is cleaved by the protease We conclude that MHC II expression is regulated in
cathepsin (Cat) S (in B cells and dendritic cells [DC]), Cat mouse DC, as in human DC, by controlling the rate of
endocytosis and subsequent degradation of peptide-




DC Cultures and Freshly Isolated DC
We have analyzed DC grown in vitro from both spleen-
and bone marrow-derived precursors. Spleen-derived
DC (“D1DC”) (Winzler et al., 1997) can be cultured in
large numbers free of other contaminating cells, they
maintain an immature phenotype indefinitely, and ma-
ture synchronously in the presence of LPS. Since the
role of CyC was first described on DC grown from bone
marrow precursors, we have also analyzed bone mar-
row-derived DC (“BMDC”) (Inaba et al., 1992). For some
experiments, we have used DC that were freshly isolated
from spleens (Vremec et al., 2000).
MHC II Is Redistributed to the Cell Surface
in Activated D1DC
D1DC upregulated the expression of CD40, CD80, CD86,
DEC-205, and MHC II after activation with LPS (Figure
1A, data not shown) (Winzler et al., 1997). The increase
in surface MHC II was not just due to augmented protein
synthesis, but to changes in MHC II trafficking. Thus,
immature D1DC accumulated MHC II in MIIC compart-
ments that were positive for the lysosomal marker Lamp
1 (Figure 1B, immature), but after stimulation with LPS
most MHC II was found at the plasma membrane of the
activated D1DC (Figure 1B, activated) (Winzler et al.,
1997).
We then examined whether the accumulation of MHC
II in MIIC was associated with the presence of CyC, and
its putative inhibition of Cat S, in the same compart-
ments. We observed little CyC in the MHC II Lamp
Figure 1. Effect of Stimulatory Signals on the Distribution of MHC
vesicles of immature DC (Figure 1C). These findings II and CyC in D1DC
thus prompted us to examine in more detail how Ii is (A) FACS analysis of the increase of MHC II and CD86 expression in
processed in D1DC before and after activation. activated D1DC. The numbers indicate the percentage of (activated)
MHC IIhi CD86hi cells. Only dead cells (propidium iodide [PI]) were
excluded (less than 5% of the total).
Ii Is Degraded Similarly in Both Immature (B) Immunofluorescence confocal microscopy (ICM) of immature
and Activated D1DC (upper panels) and activated (lower panels) D1DC. Cells were la-
beled with a rabbit anti-I-A serum (green) and with rat mAb anti-First, we determined whether MHC II-Iip10 complexes
Lamp-1 1D4B (red). The merged image is shown at the right. I-Abaccumulate in immature D1DC as they do in Cat S null
redistributed from Lamp (MIIC) compartments in immature DC toAPC (Nakagawa et al., 1999; Shi et al., 1999). MHC II
the cell surface in LPS-treated DC.
were immunoprecipitated from immature and LPS- (C) Immature D1DC were labeled with rabbit anti-CyC serum (green)
treated D1DC and from freshly isolated spleen Cat S/ plus either anti-class II mAb N22 (red, left) or rat mAb 1D4B anti-
DC. The amounts of I-A and Iip10 in each immunopre- Lamp-1 (red, right). CyC is mostly absent from MHC II, Lamp
(MIIC) compartments in immature D1DC.cipitate were then compared by Western blot (Figure
2A, left panel). The I-A chain expressed by D1DC had
a higher Mr than the one expressed by freshly isolated
spleen DC, probably reflecting differences in the glyco- associated with peptides (although its subcellular distri-
bution is differrent).sylation pattern of I-A between the two DC types (Boog
et al., 1989; Kampgen et al., 1991). The MHC II from Cat The Western blot analysis does not give information
about the kinetics of conversion of Ii complexes intoS/ DC contained large amounts of Iip10, but the bulk
of MHC II expressed by both the immature and the -peptide. We therefore followed the processing of
MHC II in D1DC by pulse-chase and immunoprecipita-activated D1DC lacked any detectable Iip10. These im-
munoprecipitates were loaded in parallel without boiling tion. Immature and LPS-activated D1DC were pulse-
labeled with 35S-Met/Cys for 45 min and then chasedto compare the relative amount of SDS-stable MHC II-
peptide complexes in each sample (see below). Cat S/ for 1, 4, 7, and 20 hr. At each time point, MHC II were
immunoprecipitated, the immunoprecipitates dividedDC contained, as expected, few SDS-stable complexes,
whereas both the immature and the activated D1DC into two, and each half run in a 12.5% SDS-PAGE after
incubation at room temperature (to score for formationexpressed large amounts (Figure 2A, right panel). This
experiment showed that immature D1DC do not lack of SDS-stable MHC II-peptide complexes) (Germain and
Hendrix, 1991) or after boiling (Figure 2B).active Cat S and that the bulk of MHC II contained at
steady state in both immature and activated cells is MHC II synthesis (determined by quantitation of the
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immunoprecipitated polypeptides) relative to total pro-
tein synthesis (determined by TCA precipitation of cell
lysates) was downregulated by one half in D1DC acti-
vated for 20 hr with LPS (the exposures shown in Figure
2B have been normalized so that the intensity of the
radiolabeled proteins in the immature and the activated
samples at the pulse time point was comparable) (Re-
scigno et al., 1998). After the pulse, MHC II were forming
Ii complexes, most of which were fully denatured at
either room temperature or 98C (Figure 2B, Pulse) (Villa-
dangos et al., 2000). These complexes were converted
into SDS-stable -peptide complexes during the
chase. This process was accompanied by the elimina-
tion of Ii (this fact is obscured because the mobility of
the I-A chain decreases due to N-linked carbohydrate
modifications when MHC II traverse the Golgi, and then
it runs at the same position as Ii) (Villadangos et al.,
2000). The -Iip10 intermediate, the substrate for Cat
S (Figures 4 and 7), was visible at the 1 hr and 4 hr time
points as a complex that was relatively stable at room
temperature and fully denatured after boiling.
The half-life of newly synthesized MHC II was clearly
shorter in immature D1DC. Thus, the number of -
peptide complexes that accumulated over time relative
to the amount of MHC II synthesized was much higher
in the activated cells that in the immature ones (Figure
2D). However, Ii degradation proceeded similarly in both
sets of cells: the amount of Iip10 relative to  at each
time point was comparable, and the majority of Ii had
been eliminated after 4 hr of chase. Moreover, the pro-
portion of MHC II that had formed SDS-stable -pep-
tide complexes at each time point was higher in the
immature cells (Figure 2E). Since the SDS-stability of
different I-Abpeptide complexes depends on the affin-
ity of their interaction, this result suggested that imma-
ture DC preferentially degraded MHC II molecules bound
to low-affinity peptides (Germain and Hendrix, 1991; Nel-
son et al., 1993).
Immature D1DC Degrade MHC II-Peptide Complexes
after Passage through the Cell Surface
Figure 2. Processing of MHC II in Immature and Activated D1DC The result of the pulse-chase experiment showed that
(A) MHC II was immunoprecipitated with mAb N22 from Cat S/ immature D1DC degraded their MHC II complexes faster
fresh spleen DC and from wild-type immature or activated D1DC. than the activated D1DC, even after the  dimers had
The immunoprecipitates were loaded in SDS-PAGE after incubation
acquired peptide cargo (after 4 hr, Figures 2B and 2D).at 98C (left) or at room temperature (right). The I-A and Iip10
Were the -peptide complexes degraded without leav-polypeptides were then detected by Western blot with rabbit sera
ing the endocytic route, or were they degraded afterspecific for the cytoplasmic portion of I-A and Ii, respectively. Most
MHC II recovered from immature and activated D1DC were forming transient expression at the plasma membrane? To an-
SDS-stable -peptide complexes. swer this question, we performed cell-surface biotinyla-
(B) Kinetics of processing of newly synthesized MHC II in immature tion after each chase time point. The MHC II immunopre-
and activated D1DC. Cells were pulse-labeled and chased for the
times indicated. I-Ab molecules were immunoprecipitated with a
rabbit anti-I-A serum, loaded in a 12.5% SDS-PAGE after incuba-
tion at room temperature (non-boiled, NB) or at 98C (boiled, B). time point (B lane). The resulting figures were represented relative
Autoradiograms of the gels are shown. The positions occupied in to the maximum value.
the gel by the free I-A and  chains, Ii, the alternatively spliced Ii (E) Relative amount of MHC II that were forming SDS-stable -
isoform Iip41 (Cresswell, 1994), and the Ii degradation intermediate peptide complexes at each time point of the pulse-chase experi-
Iip10 are indicated at the left. The SDS-stable -Iip10 and - ment. The intensity of the -peptide-containing region in each NB
peptide complexes are also indicated. lane was divided by the intensity of I-A in the corresponding B
(C) The fraction of newly synthesized MHC II that had reached the lane. The resulting figures were represented relative to the maximum
cell surface at each chase time point was reprecipitated with avidin- value.
sepharose and run in 10% SDS-PAGE. (F) The amount of biotinylated I-A at each time point was divided
(D) Accumulation of SDS-stable -peptide complexes. The values by the total amount of I-A immunoprecipitated at the end of the
of the intensity of the regions containing the SDS-stable complexes pulse. The resulting figures were represented relative to the maxi-
at each time point were divided by the intensity of I-A at the pulse mum value.
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cipitates were denatured, and the fraction of MHC II that
had reached the cell surface (i.e., accessible to biotin)
was reprecipitated using avidin-sepharose (Figure 2C).
The amount of MHC II reprecipitated with avidin at each
time point was then determined relative to the total
amount that had been synthesized by the end of the
pulse (Figure 2F).
As expected, the amount of newly synthesized MHC
II that was accessible to biotin in the activated cells
increased sharply between 1 hr and 4 hr and then de-
creased slowly (Figures 2C and 2F). This result indicated
that in activated D1DC, most of the newly synthesized
MHC II reached the plasma membrane in 4 hr as -
peptide complexes and then were slowly degraded (half-
life over 16 hr, Figure 2F). Strikingly, after 4 hr of chase,
the immature D1DC had delivered to the plasma mem-
brane 70% as many -peptide complexes as the acti-
vated D1DC (Figures 2C and 2F). However, those com-
plexes disappeared as fast as the bulk of the MHC II
synthesized by the immature D1DC (compare Figures
2B with 2C and 2D with 2F). Thus, the peptide-bound
MHC II that reached the cell surface of immature D1DC
were rapidly endocytosed and degraded. From the plot
in Figure 2F, we estimate their half-life (time to reduce
their amount from 70 to 35 a. u.) to be 4–5 hr. However,
since reinternalized complexes become inaccessible to
biotin, we could not determine the absolute amount of
newly synthesized MHC II that reached the cell surface
of the immature D1DC. It is possible that a fraction (up
to 30%) was degraded without leaving the endocytic
route.
Endocytosis and Recycling of MHC II in D1DC
The results of the pulse-chase and biotinylation experi-
ment suggested that the control of surface expression
of MHC II in D1DC did not rely on the rate of Ii degrada-
tion, but on the kinetics of re-entry of MHC II from the
Figure 3. Endocytosis of MHC II in D1DC and the Effect of Cyclohex-plasma membrane. This possibility was further investi-
imide (CHX)gated.
(A) Immature (dashed line) and activated (continuous line) D1DCTo assess the rate of endocytosis of MHC II in imma-
were incubated with biotinylated anti-MHC II mAb M5/114 at 4C,ture and activated D1DC, surface MHC II was tagged
washed, and incubated at 37C for up to 160 min. The amount of
at 4C with a biotinylated mAb. After washing off the biotinylated M5/114 remaining at the cell surface was then deter-
unbound Ab, cells were incubated at 37C for 2–160 mined by FACS analysis using avidin-FITC.
min. The amount of tagged MHC II remaining at the cell (B) Immature D1DC were incubated for 30 min with PBS (solid bars)
or 5 g/ml CHX (dashed bars). LPS was then added (dark bars),surface was then determined by FACS analysis using
and incubation continued for 9 more hours. MHC II expression wasFITC-avidin (Figure 3A). Activated D1DC endocytosed
then determined by FACS analysis.only 15% of their MHC II over the 160 min period. In
(C) Immunofluorescence microscopy of D1DC after treatment with
contrast, in their immature counterparts, the amount of CHX and/or LPS. MHC II were labeled with an anti-I-A rabbit serum
surface MHC II decreased by 1/2 in 40 min and then plus anti-rabbit-FITC. The pictures were taken using a fluorescence
stabilized at 1/3 the original level after an additional (not confocal) microscope to observe the MHC II expression in the
whole cells. The exposure times were adjusted so that the CHX-40 min. This pattern suggested that a fraction of the
treated cells were visible, causing the “burning” of the intracellularendocytosed MHC II of immature D1DC was recycled
MHC II compartments in the untreated cells.back to the plasma membrane (Cella et al., 1997). That
such recycling occurred was supported by the results
of the pulse-chase experiment, as the half-life of the ures 3B and 3C). Since the half-life of surface MHC II in
immature DC was 4–5 hr (Figure 2E), this result sup-MHC II that reached the surface of immature D1DC was
several hr (Figure 2F), not 40 min as would be expected ported the hypothesis that the majority of the MHC II
contained in the MIIC compartments of these cells (Fig-if all the endocytosed MHC II were destroyed.
We then tested the effect of the protein synthesis ure 1B) was delivered to the plasma membrane before
being degraded. Thus, even when protein synthesis wasinhibitor cycloheximide (CHX) on MHC II expression in
D1DC. After 9 hr in the presence of CHX, MHC II disap- blocked with CHX, the internal MHC II continued flowing
to the plasma membrane and substituted the fractionpeared from the intracellular compartments of immature
DC but its level at the surface remained the same (Fig- that was endocytosed and destroyed.
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Figure 4. D1DC Regulate the Expression of
the Cat S-Independent I-As Allotype
(A) Splenocytes from Cat S-deficient lit-
termates expressing I-Ab or I-As were meta-
bolically labeled for 30 min and chased for 4
hr. MHC II were immunoprecipitated with a
rabbit anti-I-A serum and loaded in a 12.5%
SDS-PAGE. The labels are the same as those
in Figure 2. In the absence of Cat S, I-Ab accu-
mulated in association with Iip10, whereas
most of I-As generated -peptide com-
plexes.
(B) Immature and activated SJL D1DC were
prepared for ICM. I-As was visualized with an
anti-I-A rabbit serum (green), and Lamp 1
was visualized with the rat mAb 1D4B (red).
I-As molecules were present mostly in
(Lamp) MIIC compartments in immature DC
and redistributed to the cell surface following
activation with LPS.
The effect of both CHX and an activatory stimulus both immature and activated cells, as was expected
(data not shown). Yet, the intracellular distribution of(LPS) was then analyzed. In this case, cell surface MHC
II augmented by 60% (Figure 3B). The milder effect of I-As in immature SJL D1DC (Figure 4B) was identical to
that of I-Ab in C57Bl/6 DC (Figure 1B). We conclude thatLPS  CHX compared to CHX alone supported the no-
tion that, when endocytosis was downregulated by acti- the pattern of expression of MHC II in D1DC does not
depend on the rate of conversion of -Iip10 into -vation, the rate of MHC II degradation also decreased.
Nevertheless, the increase in MHC II in LPS  CHX- peptide.
treated cells was far from the 300% increment observed
in cells treated only with LPS (Figure 3B). This revealed MHC II Processing Follows a Similar Pattern
in Both BMDC and D1DCthat most of the MHC II that accumulated at the surface
of activated D1DC arose from newly synthesized mole- Our results contrasted with those from a previous study
that concluded that Iip10 cleavage was inefficient incules, whereas most of the intracellular fraction was
degraded. This was confirmed because, in cells treated immature BMDC due to low Cat S activity (Pierre and
Mellman, 1998). A possible explanation for this discrep-with LPSCHX, the internal MHC II decreased as much
as in cells treated only with CHX (Figure 3C). Similar ancy could be the different origin of the DC studied. We
decided then to analyze MHC II processing in immatureresults were obtained using the ER-to-golgi transport
inhibitor brefeldin A (data not shown). We could not and activated DC grown from bone marrow precursors
(BMDC) (Figure 5A).increase the length of the treatment of the cells with
these drugs due to their toxicity. Like D1DC, immature BMDC accumulated MHC II in
MIIC compartments; whereas, in their activated counter-
parts, MHC II was expressed predominantly at the cellD1DC Control the Trafficking of Cat S-Independent
MHC II Allotypes surface (Figure 5B). CyC colocalized with Lamp com-
partments of immature BMDC to a somewhat higherSome MHC II allotypes can generate -peptide com-
plexes even in the absence of Cat S (Nakagawa et al., degree than in immature D1DC (Figure 5B).
MHC II processing was then analyzed in BMDC by1999; Villadangos et al., 1997). Figure 4A shows the
result of a pulse-chase experiment, followed by immu- pulse-chase (45 min pulse, 1, 3, and 17 hr of chase)
and immunoprecipitation (Figure 5C). Similar to D1DC,noprecipitation of MHC II, carried out with fresh spleno-
cytes from Cat S/ littermates expressing I-Ab or I-As. activated BMDC downregulated MHC II synthesis (by
70%, data not shown), and the half-life of their newlyIip10 remained attached to I-Ab, but it was expelled from
the peptide binding site of I-As, enabling the formation synthesized MHC II was higher than in immature DC
(Figure 5D). We did not observe any increase in MHCof peptide-loaded I-As molecules (Figure 7). I-Ak also
generated peptide-loaded complexes normally in a Cat II-Iip10 complexes in the immature BMDC when precipi-
tated with either an anti-I-A serum (Figure 5C) or anS null background (data not shown). Thus, if the differen-
tial expression of MHC II in immature versus activated antiserum against the N-terminal region of Ii (and Iip10)
(data not shown). Indeed, the relative number of MHCDC relied on the control of the Cat S-mediated removal
of Iip10, the distribution of I-Ak or I-As would be similar II that were forming SDS-stable -peptide complexes
at each time point was higher in the immature than in thein both immature and activated DC. Therefore, we exam-
ined the trafficking of the Cat S-independent allotype activated BMDC (Figure 5D), resembling the situation
observed with D1DC.I-As in D1DC from SJL mice.
The expression of MHC II and CD86 in SJL-derived
immature and activated D1DC resembled that of Activated DC Downregulate MHC II Expression In Vivo
A previous report showed that immature and activatedC57Bl/6 D1DC (data not shown). Processing of I-As was
analyzed by pulse-chase and immunoprecipitation, re- BMDC synthesized similar amounts of MHC II (Pierre et
al., 1997). This contrasted with our studies, in which wevealing normal formation of I-As-peptide complexes in
Immunity
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Figure 5. Expression and Processing of MHC
II in Immature and Activated BMDC
(A) Immature and activated BMDC were pur-
ifed by preparative FACS, and the expression
of CD86 and MHC II was determined as in
Figure 1A.
(B) Sorted immature and activated BMDC
were analyzed for ICM as in Figure 1B.
(C) MHC II processing was analyzed in imma-
ture and activated BMDC by pulse-chase and
immunoprecipitation as in Figure 2B.
(D) Accumulation of SDS-stable -peptide
complexes in BMDC (top) and relative frac-
tion of MHC II that were forming SDS-stable
complexes at each time point (bottom). Quan-
titation was performed as in Figures 2D
and 2E.
observed a 2- and a 3-fold reduction in MHC II produc- Discussion
tion in activated D1DC and BMDC, respectively. Late
downregulation of MHC II synthesis has been described Elimination of Ii is a prerequisite for MHC II peptide
loading that is common to all APC. Cat S is the enzymepreviously in mouse D1DC and human DC stimulated in
vitro (Cella et al., 1997; Rescigno et al., 1998). Epidermal that breaks down Iip10 in DC and B cells so that Cat
S/ DC and B cells expressing the Cat S-dependentlangerhans cells and spleen- or thymus-derived DC also
stop synthesizing MHC II after 24 hr in culture, even in allotype I-Ab accumulate -Iip10 complexes, severely
compromising their antigen presentation capacity (Na-the absence of exogenous activation signals (Kampgen
et al., 1991; Pure et al., 1990; data not shown). To assess kagawa et al., 1999; Shi et al., 1999). Studies carried out
with synthetic inhibitors of Cat S predicted that -whether inflammatory stimuli provoked the downregula-
tion of MHC II in DC activated in vivo, we purified fresh Iip10 complexes would be transported to lysosomes
and degraded (Amigorena et al., 1995; Brachet et al.,spleen DC from control- or LPS-treated mice 20 hr after
treatment. The cells were then metabolically radiola- 1997; Neefjes and Ploegh, 1992). This provided the basis
for a proposed mechanism of control of MHC II expres-beled for 60 min, and MHC I and II were immunoprecipi-
tated (Figure 6). The spleen DC from LPS-treated mice sion in DC: inactivation of Cat S by CyC would impair
Iip10 degradation, causing the retention and ultimateshowed a 3-fold reduction in MHC II synthesis and a
3-fold increase in MHC I. Thus, at least 20 hr after stimu- degradation of MHC II in immature DC (Pierre and Mell-
man, 1998).lation, MHC II synthesis is downregulated by DC acti-
vated either in vitro or in vivo. This model was questioned by studies of subcellular
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been shown previously that the proteolytic equipment
of different mouse strains is similar (Villadangos et al.,
1997). However, the subcellular distribution of (Cat S-inde-
pendent) I-As in DC derived from SJL mice resembled
that of (Cat S-dependent) I-Ab in C57Bl/6-derived DC
(Figures 1 and 4). We conclude that the control of MHC
II expression in DC does not depend on the extent or
rate of degradation of Iip10. This is consistent with the
observation that DC control the expression of I-Ak in an
Ii-null background (Rovere et al., 1998).
A previous study showed by Western blot that imma-
ture BMDC contained a larger amount of Iip10 in low-
density compartments than their activated counterparts
(Pierre and Mellman, 1998). However, it was unclear if
this was because Iip10 degradation was impaired in
immature DC, or rather because the immature cells pro-
Figure 6. Spleen DC Downregulate MHC II Synthesis In Vivo cessed with normal kinetics a larger amount of MHC II.
Two C57Bl/6 mice were injected i.v. with PBS, and two were injected Indeed, we observed a 2- to 3- fold reduction in the
with 30g LPS. After 20 hr, the spleen DC were purified and metabol- amount of MHC II synthesized by DC after activation
ically labeled for 1 hr. MHC II and MHC I were then immunoprecipi- with LPS either in vitro or in vivo, a result consistent
tated sequentially using mAb N22 and Y3P, respectively. HC indi-
with previous studies of DC activation in vitro (Cella etcates MHC I heavy chain.
al., 1997; Rescigno et al., 1998). Immature DC are thus
processing at steady state several times more MHC II
than activated DC. This could cause an increase in thefractionation of activated wild-type and Cat S/ DC,
absolute number of MHC II-Iip10 complexes containedwhich showed that both -Iip10 and -peptide can
in the endocytic compartments of the immature DC. Inbe transported from lysosomal compartments to the
fact, an earlier study showed, as we do here, that MHCplasma membrane (Driessen et al., 1999). Moreover, Cat
II acquired peptide cargo in immature BMDC more effi-S/ APC express at their surface wild-type levels of
ciently than in their activated counterparts (Pierre et al.,MHC II, of which at least 50% are -Iip10 complexes
1997).(Driessen et al., 1999; Nakagawa et al., 1999; Shi et al.,
Since Cat S activity appears to be comparable in im-1999). Consistent with these studies, LPS-activated Cat
mature and activated DC (at least with regards to IiS/ D1DC delivered more MHC II to their plasma mem-
degradation), our data do not support a role for CyC inbrane than their immature counterparts but maintained
regulating MHC II expression in DC. We observed littlemore intracellular MHC II than wild-type activated DC
colocalization of CyC in MIIC compartments of both(our unpublished data). This probably reflected slow
immature and activated D1DC (Figure 1C). CyC appearedtransport of MHC II (in part as -Iip10) to the surface
more widely distributed in immature BMDC (Figure 5B),of the Cat S/ DC following activation. Thus, failing to
but this probably reflected lineage-specific differencesremove Iip10 slows down the egress of MHC II, but only
in CyC expression and/or subcellular localization amongimmature DC express low levels of MHC II regardless of
DC types. Indeed, CyC is differentially expressed in dis-Cat S activity. Is this because the Ii-dependent retention
tinct populations of spleen DC (our unpublished data).system is more efficient in immature DC, or is it because
Nevertheless, if CyC has a role in DC, this does notDC control MHC II expression by a Cat S-independent
appear to be the control of MHC II expression. Similarmechanism?
conclusions were reached in a recent study of human
DC (Fiebiger et al., 2001).MHC II Expression Is Regulated in DC Independently
of the Efficiency of Ii Degradation
Our pulse-chase analysis showed that immature and Control of MHC II Expression in DC as a Consequence
of Different Endocytic Activityactivated D1DC or BMDC degraded Ii and generated-
peptide complexes with comparable kinetics (Figures 2 We propose an alternative mechanism analogous to a
model proposed previously for human DC (Cella et al.,and 5). Thus, most of the MHC II present at steady
state in both the immature and activated D1DC were 1997). According to this model (Figure 7), immature DC
convert their newly synthesized Ii complexes into -not associated with Iip10, but with peptides (Figure 2A),
albeit distributed differently (Figure 1B). peptide normally (Figure 2B). A fraction of the -pep-
tide complexes may be transported directly to lyso-Comparing C57Bl/6- with SJL-derived DC has allowed
us to further evaluate the role of Iip10 degradation in somes and eliminated, but probably most are transiently
expressed at the plasma membrane, reendocytosed,the control of MHC II expression. In the absence of Cat
S, some MHC II allotypes (I-Ab and d) remain associated and then degraded (Figures 2A and 2E). Rapid internal-
ization of MHC II in immature D1DC was demonstratedwith Iip10, but others (I-Ak, q, s, and u) are converted into -
peptide (Nakagawa et al., 1999; Villadangos et al., 1997) by FACS analysis and biochemically (Figures 2C, 2F,
and 3A). The fact that stopping protein synthesis for 9(Figure 4). This difference in the requirement for Cat S
is unlikely to be caused by variations in the genetic hr did not reduce the level of surface MHC II in immature
DC, but provoked the disappearance of the internal MHCbackground outside the MHC because the animals used
in the experiment in Figure 4 were littermates and it has II pool, supports the interpretation that the intracellular
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Figure 7. Trafficking and Processing of MHC II in Immature and Activated DC
Newly synthesized MHC II assemble in the endoplasmic reticulum as Ii. Ii is processed in CIIV/MIIC compartments first by one or more yet
unknown noncysteine proteases to generate Iip10. Iip10 is then cleaved by Cat S (white arrow), and the  dimers are loaded with antigenic
peptides. If Cat S is inactive, -Iip10 complexes accumulate (I-Ab or d) or are directly converted into -peptide (I-Ak, q, s, and u, dashed line),
depending on the MHC II allotype (reviewed in Villadangos and Ploegh, 2000). MHC II acquire peptide cargo in both immature and activated
DC, but are degraded in the first after transient expression at the plasma membrane. The width of the arrows indicates the relative flow of
MHC II among subcellular locations. The size of the boxes represents the relative amount of MHC II in each location at steady state. Some
of the MHC II trafficking pathways have been removed for simplicity; the complexity of the endocytic route is also higher than suggested in
this scheme.
MHC II is delivered to the cell surface before being BMDC (Figures 1, 2, and 5), it is reasonable to infer that
the mechanisms employed by both DC types to controldegraded (Figures 3B and 3C).
The kinetics of endocytosis of MHC II in immature MHC II expression are also similar. Besides, the property
of some MHC II allotypes to acquire peptide cargo inD1DC suggested that a fraction of the internalized mole-
cules recycled back to the cell surface (Askew et al., the absence of Cat S has been observed in all the APC
analyzed so far (Nakagawa et al., 1999; Villadangos et2000; Bakke and Nordeng, 1999; Cella et al., 1997). The
SDS-stability of the MHC II-peptide complexes that sur- al., 1997), so it is unlikely that BMDC would be different
in this respect to other APC. Still, we do not discard thevived in immature DC was significantly higher than in
the activated DC (Figure 2), suggesting that peptide possibility that, in immature BMDC or other DC types,
the proportion of -peptide complexes that is de-editing might accompany the process of recycling of
MHC II, favoring the survival of high-affinity complexes graded without reaching the plasma membrane might
be higher than in D1DC.(Kropshofer et al., 1997). The intracellular pool of MHC II
in immature DC thus corresponds to newly synthesized
molecules undergoing conversion into -peptide, mol- Do Immature DC Present Self-Antigenic Determinants?
Two reports have shown that immature DC retained theecules that are on their way to being degraded in lyso-
somes, and molecules being recycled back to the cell model antigen hen egg lysozyme (HEL) in endosomal com-
partments that also contained MHC II (the Cat S-indepen-surface (Figure 7).
In activated DC, endocytosis is drastically reduced dent allotype I-Ak) and H-2DM. However, I-Ak did not
accumulate in association with HEL-derived peptides(Garrett et al., 2000; Sallusto et al., 1995; Winzler et al.,
1997). In this situation, the rate of reentry and degrada- at levels detectable by microscopy until the DC received
an activatory stimulus (Inaba et al., 2000; Turley et al.,tion of MHC II would decrease (Figure 7). Shortly after
activation, MHC II synthesis is upregulated, but then it 2000). These results suggested that immature DC lacked
peptide-receptive I-Ak, presumably as a consequencedecreases (Cella et al., 1997; Rescigno et al., 1998) (Fig-
ure 6). Thus, the MHC II peptide complexes generated of low Cat S activity, and therefore could not present
peptides derived from self proteins (or from nonself pro-after contact with the activatory stimulus (i.e., a bacterial
or a viral product, or an endogenous signal) (Banchereau teins included in the culture medium). Our results do
not support this hypothesis: the MHC II synthesized byet al., 2000) accumulate at the cell surface, where they
are long-lived (Figure 7). The largest contribution to the both the immature and the activated DC were constantly
acquiring peptide cargo. Indeed, immature DC did ex-increase in surface MHC II in activated DC is provided by
newly synthesized molecules and not by the preexisting press I-Ak  HELpep complexes; albeit, of course, at
lower levels than activated DC, as demonstrated byinternal pool, which is suggested because the increase
in surface MHC II in LPS-treated cells was five times FACS analysis and T cell proliferation assays (Inaba et
al., 2000). Moreover, it is unlikely that I-Ak accumulateshigher than in cells treated with LPS  CHX (Figure 3B).
Some of the experiments supporting this model have as Iip10-associated complexes in immature DC since,
like I-As, this allotype can acquire peptide cargo nor-been carried out only on D1DC because we could not
obtain the large numbers of pure BMDC necessary to mally, even in a Cat S null background (Figure 4, our
unpublished data). The model that we propose and re-perform experiments of pulse-chase followed by bio-
tinylation. However, given the similarity in the subcellular cent data from other laboratories support an alternative
explanation.distribution and processing of MHC II in D1DC and
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rabbit serum was from Amrad, and the anti-rat sera coupled to FITCFirst, the activity of endosomal proteases increases
or Texas red were from Serotec.when DC receive an inflammatory stimulus (Fiebiger et
al., 2001). Therefore, whereas the basal proteolytic activ-
Splenocytes and Isolation of Splenic DC
ity of immature DC can supply the bulk of peptides Single-cell suspensions of splenocytes were prepared in pulse me-
that are incorporated into MHC II-peptide complexes dium (see below). Fresh spleen DC were purified as described
(Figures 2 and 5), each individual antigen is probably (Vremec et al., 2000).
degraded more efficiently in activated DC. Second, the
Spleen-Derived DC Cultures (D1DC)half-life of MHC II-peptide is shorter in the immature
D1DC were grown in vitro in our laboratory from spleen precursorsDC. Consequently, the I-Ak  HELpep complexes may
as described (Winzler et al., 1997). Over 95% of the cells werebe generated less efficiently, and degraded faster, in
CD11c, MHC II, CD40, CD80, and CD86 (Figures 1A and data
immature DC, thus preventing their accumulation at lev- not shown). Cells were activated by incubation in 1 g/ml LPS
els detectable by microscopy. Upon receipt of an inflam- (Sigma) for 20 hr.
matory stimulus, the combined effect of a higher proteol-
Bone Marrow-Derived DC (BMDC)ysis of HEL, together with an increase in the half-life of
BMDC were generated using a modification of the method of Inabathe I-Ak  HELpep complexes, could account for their
et al. (Inaba et al., 1992). Cells were flushed from the bone marrowaccumulation in the activated DC. In addition, the phys-
cavity with PBS, 2.5% FCS, and the erythrocytes were removed by
ico-chemical properties (i.e., pH or redox potential) of osmotic shock. Cells were plated at 6 106 cells/well in 3 ml RPMI
the MIIC of immature DC might be milder than those of 1640, 10% FCS and 1 ng/ml GM-CSF with or without 1 ng/ml IL-4.
activated DC; HEL could be relatively more sensitive to Nonadherent cells were removed by gentle washing at day 2, and
half the medium was replaced. Nonadherent cells (including DC)these changes than the bulk of the proteins that supply
were harvested at day 4. For activation, 1 g/ml LPS was addedthe peptides presented by MHC II (Fiebiger et al., 2001).
for the last 20 hr of culture. Immature BMDC were labeled for prepar-Understanding the mechanisms that control MHC II
ative FACS with anti-CD86 GL1 and anti-CD11c N418 and purified
expression in DC may lead to ways of enhancing the as CD11cCD86lo using a FACS II, FACStarplus (Beckton-Dickinson)
efficiency of DC-based vaccines or, conversely, to abro- or Mo-Flo (Cytomation) instrument. Activated BMDC were labeled
gate the presentation of autoantigens (Fong and Engle- only with N418 and purified as CD11c. Inclusion of IL-4 dramatically
increased the yield of LPS-treated BMDC. The experiments decribedman, 2000; Thomas et al., 1999). It is likewise important
in Figure 5 were carried out with BMDC grown in GM-CSF  IL-to establish whether immature DC present self-antigenic
4-supplemented cultures; similar results were obtained with cellsdeterminants, since this may have implications for un-
purified from cultures supplemented only with GM-CSF (data not
derstanding their role in inducing tolerance (Banchereau shown).
et al., 2000). Our study supports a model for the control
of MHC II antigen presentation in DC that could function Pulse-Chase Analysis and Biotinylation
on both Cat S-dependent and Cat S-independent allo- Cells were incubated in pulse medium (methionine/cysteine-free
DMEM supplemented with 10% FCS and 2 mM L-glutamine) for 45types and also in the absence of Ii (Rovere et al., 1998).
min, pulse-labeled with 1 mCi/ml 35S-methionine/cysteine (Du PontIn this scenario, immature DC are constantly presenting
New England Nuclear), spun down, and then resuspended in com-at their surface antigenic determinants derived from self
plete RPMI 1640, 10% FCS, 2mM glutamine (splenocytes and fresh
components, but at lower levels and for a shorter time spleen DC), R1 medium (D1DC), or BMDC medium. Cells were spun
than activated DC. A similar scenario has been proposed down immediately (pulse) or after incubation for the indicated times
previously by Cella et al. for human DC (Cella et al., (chase) and frozen. For biotinylation, cells were washed twice at the
end of each chase time point with ice-cold PBS and then incubated1997). Our study thus supports a unifying model to ex-
for 30 min at 4C in PBS containing 5 mg/ml EZ-linkTM Sulfo-NHS-plain the control of MHC II expression in DC that can
LC-biotin (Pierce). Cells were then washed three times with PBS,operate across species regardless of the individual al-
10% FCS and frozen.
lotype.
Immunoprecipitation, SDS-PAGE, and Quantitation
Experimental Procedures Immunoprecipitations were performed as described (Villadangos et
al., 1997). Immunoprecipitates were resuspended in reducing sam-
Mice ple buffer, incubated for 5 min at room temperature or 98C, and
Mice were bred at the Walter and Eliza Hall Institute animal breed- analyzed by SDS-PAGE. The efficiency of incorporation of 35S-Met/
ing facility. Cat S/mice were provided by Dr. H.A. Chapman (UCSF, Cys during metabolic labeling was evaluated by TCA precipitation
San Francisco, CA). of 10 l cell lysate. Quantitation of the radioactive polypeptides was
performed using a Molecular Dynamics phosphorimager.
Flow Cytometric Analysis
The following mAb were used for fluorescence-activated cell-sorting Western Blot
(FACS) analysis as described elsewhere (Vremec and Shortman, After SDS-PAGE, proteins were transferred to an Immobilon-P PVDF
1997; Vremec et al., 1992): anti-MHC II (not I-As) N22 and anti-I-As membrane (Millipore). The membrane was blocked, incubated with
10–2.16 conjugated to Cy5; anti-CD40 FGK45.5, anti-CD80 16–10A1, an anti-I-A rabbit serum, and then with an HRP-coupled anti-rabbit
and anti-CD86 GL1 conjugated to FITC; and anti-CD11c N418 and goat serum (Sigma). Detection was performed using the Supersignal
anti-DEC 205 NLDC145 conjugated to PE. Samples were analyzed Chemiluminescence Substrate (Pierce). The membrane was
using a FACS II, FACStarPlus of FACScan instrument (Becton Dick- washed, and the same procedure was repeated using an anti-Ii
inson). rabbit serum as the primary antibody.
Confocal ImmunomicroscopyAntibodies for Microscopy, Immunoprecipitation,
and Western Blot Glass coverslips were incubated for 1 hr with 10 g/ml mAb N22
(for C57Bl/6 DC) or 10–2.16 (for SJL DC) in PBS and washed. Imma-The anti-I-A and anti-Ii (N-terminus) rabbit sera have been de-
scribed (Driessen et al., 1999). The rat anti-Lamp 1 mAb 1D4B was ture and activated DC were plated in R1 medium (/ LPS) on the
coverslips and incubated for 30–60 min at 37C to allow the cellsfrom Pharmingen. The anti-CyC rabbit serum was from Upstate
Biotechnology. Texas red-avidin was from Amersham, the FITC anti- to attach and spread. Cells were fixed for 10 min with 4% paraformal-
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dehyde, washed, and then permeabilized 15 min with 0.05% saponin S., Muramatsu, S., and Steinman, R.M. (1992). Generation of large
numbers of dendritic cells from mouse bone marrow cultures sup-in PBS containing 10% normal goat serum (NGS). Cells were incu-
bated with the primary antibody diluted in permeabilization buffer for plemented with granulocyte/macrophage colony-stimulating factor.
J. Exp. Med. 176, 1693–1702.30 min, washed three times, and then incubated with the secondary
antibody for 30 min in permeabilization buffer. After washing, the Inaba, K., Turley, S., Iyoda, T., Yamaide, F., Shimoyama, S., Reis e
coverslips were mounted on microscopy slides and analyzed in Sousa, C., Germain, R.N., Mellman, I., and Steinman, R.M. (2000).
a Leitz Fluovert FU (Leica) confocal microscope. No intracellular The formation of immunogenic major histocompatibility complex
staining was observed in the absence of saponin, and no staining class II-peptide ligands in lysosomal compartments of dendritic cells
occurred if the primary antibodies were omitted. is regulated by inflammatory stimuli. J. Exp. Med. 191, 927–936.
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